Patient Registry Safety Study for Grass MATA MPL (1.0 ml)

Trial Profile

Patient Registry Safety Study for Grass MATA MPL (1.0 ml)

Phase of Trial: Phase IV

Latest Information Update: 09 Jan 2015

At a glance

  • Drugs Grass pollen allergy immunotherapy (Primary) ; Monophosphoryl lipid A
  • Indications Grass pollen hypersensitivity; Rhinoconjunctivitis; Seasonal allergic rhinitis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Allergy Therapeutics
  • Most Recent Events

    • 09 Jan 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top